Mumbai, Apr 2 (TNT): Lupin Limited on Thursday announced the completion of its acquisition of VISUfarma B.V. from GHO Capital Partners LLP, marking a significant step in strengthening its specialty care business and expanding its footprint in Europe.
With this acquisition, Lupin’s ophthalmology portfolio has expanded to over 60 branded products covering dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals.
VISUfarma brings with it a strong commercial presence across key European markets, including Italy, the UK, Spain, Germany, and France, supported by an experienced team and established market relationships.
In a release, the pharma company said the acquisition enhances its ability to cater to the growing global demand for advanced eye care solutions, driven by an ageing population and rising cases of diabetes-related eye disorders.
Lupin CEO Vinita Gupta said the deal represents a major milestone, adding a differentiated portfolio of innovative eye health products and strengthening the company’s specialty pharmaceutical franchise in Europe.
VISUfarma’s CEO Italy Paolo Cioccetti said the partnership with Lupin would help accelerate growth and innovation in ophthalmology, enabling the combined entity to expand access to advanced eye care solutions across Europe and beyond.
The acquisition is expected to be immediately accretive and aligns with Lupin’s long-term strategy to build a strong global specialty business.
TNT KS
Leave a Reply